Carlsmed, a spine company developing personalized implants, saw a 99% increase in its second quarter revenue year over year, according to financial results posted Aug. 28.
Five things to know:
1. Second-quarter revenue was $12.1 million compared to $6.1 million the same period in 2024.
2. Carlsmed’s personalized cervical spine implant was used in its first case during the second quarter. The procedure also earned CMS New Technology Add-On Payment reimbursement, which goes into effect in October.
3. Operating expenses grew year over year at $15.4 million. Most of those expenses were related to sales and marketing and research and development.
4. Carlsmed saw a net loss of $6.8 million.
5. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo technology platform and growing recognition of its ability to deliver more favorable patient outcomes than legacy devices,” Chair and CEO Mike Cordonnier said in a news release. “Building upon our momentum in personalized lumbar fusion surgery, in July we successfully completed the first personalized cervical spine surgery using our aprevo technology platform, launching in 2026. We enter the second half of 2025 well positioned for continued scale as we become the new standard of care in spine fusion surgery.”
